Uterine Fibroids - Pipeline Insight, 2021

Uterine Fibroids - Pipeline Insight, 2021

  • July 2021 •
  • 60 pages •
  • Report ID: 5974312 •
  • Format: PDF
“Uterine Fibroids - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Uterine Fibroids pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Uterine Fibroids Understanding

Uterine Fibroids: Overview
Uterine fibroids are benign (not cancer) growths that develop from the muscle tissue of the uterus. They also are called leiomyomas or myomas. The size, shape, and location of fibroids can vary greatly. They may be inside the uterus, on its outer surface or within its wall, or attached to it by a stem-like structure. A woman may have only one fibroid or many of varying sizes. A fibroid may remain very small for a long time and suddenly grow rapidly, or grow slowly over a number of years. Fibroids are most common in women aged 30–40 years, but they can occur at any age. Fibroids occur more often in African American women than in white women. They also seem to occur at a younger age and grow more quickly in African American women.

"Uterine Fibroids - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Uterine Fibroids pipeline landscape is provided which includes the disease overview and Uterine Fibroids treatment guidelines. The assessment part of the report embraces, in depth Uterine Fibroids commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Uterine Fibroids collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Uterine Fibroids R&D. The therapies under development are focused on novel approaches to treat/improve Uterine Fibroids.

Uterine Fibroids Emerging Drugs Chapters
This segment of the Uterine Fibroids report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Uterine Fibroids Emerging Drugs
• Elagolix: AbbVie
Elagolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, is an orally administered, short-acting molecule that blocks endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration results in readily reversible, dose-dependent inhibition of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to reduced ovarian production of the ovarian sex hormones, estradiol and progesterone, while on therapy. Elagolix is currently being investigated in diseases that are mediated by ovarian sex hormones, such as uterine fibroids and endometriosis. The drug is currently in phase III stage of development to treat uterine fibroids.

• Linzagolix (KLH-2109): ObsEva
Linzagolix is a novel, orally administered GnRH receptor antagonist. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately reducing estrogen production by the ovaries. In November 2015, Kissei lincesed out exclusive rights to develop and market in countries excluding part of Asia such as Japan to ObsEva. The drug is currently in preregistration stage of development to treat uterine fibroids.
Further product details are provided in the report……..

Uterine Fibroids: Therapeutic Assessment
This segment of the report provides insights about the different Uterine Fibroids drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Uterine Fibroids
There are approx. 10+ key companies which are developing the therapies for Uterine Fibroids. The companies which have their Uterine Fibroids drug candidates in the most advanced stage, i.e. preregistration include, ObsEva.

• Phases
This report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Uterine Fibroids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Uterine Fibroids: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Uterine Fibroids therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Uterine Fibroids drugs.

Uterine Fibroids Report Insights
• Uterine Fibroids Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Uterine Fibroids Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Uterine Fibroids drugs?
• How many Uterine Fibroids drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Uterine Fibroids?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Uterine Fibroids therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Uterine Fibroids and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• AbbVie
• ObsEva
• Repros Therapeutics
• Bayer HealthCare Pharmaceuticals
• Ogeda
• Context Therapeutics
• Addex Pharmaceuticals

Key Products
• Elagolix
• Linzagolix (KLH-2109)
• Telapristone Acetate
• Vilaprisan
• Fezolinetant
• CTX 030916